{"name":"Ahon Pharmaceutical Co., Ltd.","slug":"ahon-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"FCN-437c,Fulvestrant,Goserelin acetate","genericName":"FCN-437c,Fulvestrant,Goserelin acetate","slug":"fcn-437c-fulvestrant-goserelin-acetate","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women","status":"phase_3"},{"name":"Placebo,Fulvestrant,Goserelin acetate","genericName":"Placebo,Fulvestrant,Goserelin acetate","slug":"placebo-fulvestrant-goserelin-acetate","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ET-26","genericName":"ET-26","slug":"et-26","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"ET-26","genericName":"ET-26","slug":"et-26","phase":"phase_3","mechanism":"ET-26 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"FCN-437c,Fulvestrant,Goserelin acetate","genericName":"FCN-437c,Fulvestrant,Goserelin acetate","slug":"fcn-437c-fulvestrant-goserelin-acetate","phase":"phase_3","mechanism":"This combination therapy uses an estrogen receptor degrader (fulvestrant) and a gonadotropin-releasing hormone agonist (goserelin) to suppress estrogen signaling in hormone receptor-positive breast cancer.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women"],"catalyst":""},{"name":"Placebo,Fulvestrant,Goserelin acetate","genericName":"Placebo,Fulvestrant,Goserelin acetate","slug":"placebo-fulvestrant-goserelin-acetate","phase":"phase_3","mechanism":"This combination uses fulvestrant to block estrogen receptors in cancer cells and goserelin to suppress ovarian hormone production, while placebo serves as a control arm.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in premenopausal women"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}